Portopulmonary hypertension caused by portal hypertension that is complicated by central diabetes insipidus
Open Access
- 11 February 2020
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 8 (3) , 520-522
Abstract
We discuss the pathophysiology, diagnosis, differential diagnosis, and therapy of a case with central diabetes insipidus, idiopathic portal hypertension, and portopulmonary hypertension. This report reviews how vasopressin affects those diseases.Keywords
Funding Information
- Department of Education of Liaoning Province (JG16DB086)
This publication has 7 references indexed in Scilit:
- Atipik Prezente Kist Hidatik: Pankreas Başında KitleSakarya Medical Journal, 2018
- The Changing Role of Sodium Management in CirrhosisCurrent Treatment Options in Gastroenterology, 2016
- Pulmonary Langerhans cell histiocytosis: A comprehensive analysis of 40 patients and literature reviewEuropean Journal of Internal Medicine, 2015
- “Porto-pulmonary hypertension: A comprehensive review”Clinics and Research in Hepatology and Gastroenterology, 2015
- The Effect of Vasopressin and Related Compounds at V1aand V2Receptors in Animal Models Relevant to Human Disease*Basic & Clinical Pharmacology & Toxicology, 2006
- Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signalingJournal of Thrombosis and Haemostasis, 2003
- Desmopressin is a Potent Vasorelaxant of Aorta and Pulmonary Artery Isolated from Rabbit and RatAnesthesiology, 1990